| Bioactivity | VU0155041 sodium is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD)[1]. |
| Invitro | VU0155041 (10 μM) does not affect NMDA receptor currents in striatal medium spiny neurons[1]. |
| In Vivo | VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy induced by the dopamine D2 receptor antagonist Haloperidol (1.5 mg/kg, i.p.) in rats[1].VU0155041 (93 nmol, 316 nmol; i.c.v.) reverses Reserpine (HY-N0480) -induced akinesia in rats[1]. Animal Model: |
| Name | VU0155041 sodium |
| CAS | 1259372-69-4 |
| Formula | C14H14Cl2NNaO3 |
| Molar Mass | 338.16 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Niswender CM, et, al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol. 2008 Nov; 74(5): 1345-58. |
VU0155041 sodium
CAS: 1259372-69-4 F: C14H14Cl2NNaO3 W: 338.16
VU0155041 sodium is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM f
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.